Medullary carcinoma of the thyroid

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 5, Issue 2, 1997, Pages 55-66

  Randolph, Gregory W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; TUMOR MARKER;

FAMILIAL CANCER; GENETIC LINKAGE; GENETIC SCREENING; HUMAN; NECK DISSECTION; ONCOGENE; PRIORITY JOURNAL; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 0031010318     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/00020840-199704000-00001     Document Type: Review

References (85)

1. Block MA: Clinical characteristics distinguishing hereditary from sporadic MTC. Arch Surg 1980, 115:142-148.
2. Hazard JB, Hawk WA, Crile G Jr: Medullary (solid) carcinoma of the thyroid: a clinopathologic entity. J Clin Endocrinol Metab 1959, 19:152-161.
3. Steiner AL, Goodman AD, Powers SR: Study of the kindred with pheochromocytoma, medullary carcinoma of the thyroid, hyperparathyroidism and Cushing's disease: MEN Type II. Medicine 1968, 47:371-409.
4. Eng C: The RET proto-oncogene in MEN type II and Hirschsprung's •• disease. N Engl J Med 1996, 335:943-951. An up-to-date review of RET protooncogene findings in MEN II with significant clinical orientation.
5. Gagel RF, Cote G: Decision making In MEN Type II. In Advances in Endocrinology and Metabolism, vol 5, Edited by Mazzaferri EL, Bar RS, Kreisberg RA, eds. St. Louis: Mosby; 1994:1-23.
6. Chong GC, Beahrs OH, Sizemore GW, Woolner L: Medullary carcinoma of the thyroid. Cancer 1975, 35:695-704.
7. O'Riordam D, O'Brien T, Crotty T, et al.: Multiple endocrine neoplasia Type IIb: more than an endocrine disorder. Surgery 1995, 118:936-942.
8. Farndon JR, Leight GS, Dilley WG, et al.: Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Brit J Surg 1986, 73:278-281.
9. Olson JE, Hughes J, Alpern H: Family members of patients with sporadic medullary thyroid carcinoma must be screened for hereditary disease. Surgery 1992, 112:1074-1079.
10. Sizemore GW, Carney JA, Heath H: Epidemiology of medullary carcinoma of the thyroid. Surg Clin North Am 1977, 57:633-645.
11. Saad MF, Ordonez NG, Rashid RK, et al.: Medullary thyroid carcinoma: a study of the clinical features and prognostic factors in 161 patients. Medicine 1984, 63:319-342.
12. American Joint Committee on Cancer: Manual for Staging of Cancer, edn 3. Edited by Beahrs OH, Henson DE, Hutter RVP, Myers MH. Philadelphia: JB Lippincott Company; 1988.
13. Dunn JM, Farndon JR: Medullary thyroid carcinoma. Br J Surg 1993, 80:6-9.
14. Grauer A, Raue F, Gagel R: Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am 1990, 19: 613-635.
15. Hollenberg CH: Medullary carcinoma of the thyroid. Arch Otolaryngol 1983, 109:103-105.
16. Baylin SB, Hsu SH, Gann DS, Smallridge RC, Wells SA Jr: Inherited MTC: a final monoclonal mutation In multiple clones of susceptible cells. Science 1978, 199:429-431.
17. Knudson AG Jr, Strong LC, Anderson DE: Heredity and cancer in man. Medicine 1973, 9:133-158.
18. Eng C, Mulligan L, Smith D, Healey CS, Frilling A, Rave F, Neumann H, • Behmel A, Lorenzo M: Mutation of RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chromosom Cancer 1995, 12:209-212. Genetic analysis of sporadic MTC tumors show somatic, not germline, RET mutation in codon 918, not found in MEN IIa. This may help to differentiate sporadic from inherited cases, yet further links sporadic and inherited MTC tumors through a common oncogene.
19. Gagel RF, Cote G, Martins BM, Boyd M, Cumming T, Goepfert H, Evans •• D, et al.: Clinical use of molecular information in the management of multiple endocrine neoplasia type IIa. J Intern Med 1995, 238:333-341. An up-to-date comprehensive review of genetic testing and controversies related to its clinical applications.
20. Gagel RF, Robinson MF, Donovan D, Alford B: Clinical review 44: medullary thyroid carcinoma recent progress. J Clin Endocrinol Metab 1993, 76:809-814.
21. Mulligan LM, Kwok JBJ, Healey CS, Elsdon C, Eng C, Gardner E, Love D, Mole S, Moore J, et al.: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type II. Nature 1993, 363:458.
22. Donis-Keller H, Dou S, Chi D, Carlson K, Toshima K, Lairmore T, Howe T: Mutations in the RET proto-oncogene are associated with MEN lia and FMTC. Hum Mol Genet 1993, 2:851-856.
23. Eng C, Smith DP, Mulligan LM, Nagai M, Healey C, Ponder M, Gardner E: Point mutation within the tyrosine kinase domain of the RET protooncogene in MEN Type lib and related sporadic tumors. Hum Mol Genet 1994, 3:237-241.
24. Landsratr RM, Jansen RP, Hofstra RM, Buys C, Lips C, Amstel H: Mutation analysis of the RET proto-oncogene in Dutch families with MEN IIa, MEN IIb, and FMTC. Two novel mutations and one de novo mutation for MEN IIa. Hum Genet 1996, 97:11-14.
25. Frilling A, Dralle H, Eng C: Presymptomatic DNA screening in families with multiple endocrine neoplasia Type II and familial MTC. Surgery 1994, 118:1099-1104.
26. Decker RA, Peacock ML, Borst MJ, Sweet J, Thompson N: Progress In • genetic screening of MEN Type IIa: is calcitonin testing obsolete? Surgery 1995, 118:257-264. A comparison of biochemical versus genetic screening in MEN IIa, defining the important role of RET oncogene testing.
27. Pasini B, Hofstra R, Yin L: The physical map of the human RET protooncogene. Oncogene 1995, 11:1737-1743.
28. Mulligan LM, Ponder BAJ: Genetic basis of endocrine disease MEN Type II. J Clin Endocrinol Metab 1995, 80:1989-1995.
29. Lloyd RV: RET proto-oncogene mutation and rearrangements in endocrine disease. Am J Pathol 1995, 147:1539-1544.
30. Takahashi M: Oncogenic activity of the RET proto-oncogene in thyroid cancer. Crit Rev Oncog 1995, 6(1):35-46.
31. Santoro M, Carlomagno F, Romano A, Bottaro D, Dathan N, Fusco A, Vecchio G, Matostova B, et al.: Activation of RET as a dominant transforming gene by germline mutations of MEN IIa and MEN IIb. Science 1995, 267:381-383.
32. vanHeyningen V: One gene: four syndromes. Nature 1994, 367:319-320.
33. Marsh DJ, Andrew SD, Eng C: Germline and somatic mutations in an •• oncogene: RET mutations in inherited MTC. Cancer Res 1996, 56:1241-1243. Identification in some inherited MTC of both germline and somatic RET mutations, as in Knudson's two mutation model.
34. Komminoth P, Kunz E, Matias-Guiu X, Hiort D, Christensen G, Colomer A: Analysis of RET oncogene point mutations distinguishes heritable from non-heritable medullary thyroid carcinomas. Cancer 1995, 76:479-489.
35. Eng C, Smith D, Mulligan LM, Healey C, Zvelebil M, Stonehouse T, Ponder M: A novel point mutation In the tyrosine kinase domain of the RET proto-oncogene in sporadic MTC and in a family with FMTC. Oncogene 1995, 10:509-513.
36. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Backdahl M, Weber G, Wallin G: Mutation of the codon 918-the RET proto-oncogene correlates to poor prognosis In sporadic MTC. J Clin Endocrinol Metab 1995, 80:3088-3090.
37. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R, Nishisho I, •• Takai S, et al.: The relationship between specific RET proto-oncogene mutations and the disease phenotype in MEN II: International RET mutation consortium analysis. JAMA 1996, 276:1575-1579. An international RET mutation consortium analysis relating genotype (RET codon mutation locus) and phenotype in MEN II.
38. Frank-Raue K, Hoppener W, Frilling A, Kotzerke J, Dralle H, Haase R, Rendt J, et al.: Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relationship between genotype and phenotype. J Clin Endocrinol Metab 1996, 81:1780-1783.
39. Marsh DJ, Learoyd BL, Robinson BG: Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995, 5:407-424.
40. Wells S, Chi D, Toshima K, Dehner L, Coffin C, Dowton B, Ivanovich T, Dilley W, Moley J: Predictive DNA testing in prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type II. Ann Surg 1994, 220:237-250.
41. Marsh DJ, McDowall D, Valentine J, Hyland V, Andrea S, Schunteter M, Gaskin E, Nevell D, Delbridge L, Clifton-Bligh P: The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN IIa families. Clin Endocrinol 1996, 44:213-220.
42. Lips CJ, Landsvater RM, Hoppener JW, Geerdint R, Bligham G, Dewit M, Zewold R, Berends M, et al.: Clinical screening as compared with DNA analysis in families with MEN Type IIa. N Engl J Med 1994, 331:828-835.
43. Pacini F, Romei C, Miccoli P, Hiser R, Molioro E, Mancosi F, Basolo F, Martino E, Pinchera A: Early treatment of hereditary medullary thyroid carcinoma after attribution of MEN Type II gene carrier status by screening for RET gene mutation. Surgery 1995, 118:1031-1035.
44. Lips CJ, Landsvater RM, Hoppener JW, Geerdink R, Bligham G, Hoogenboom H, Berends M, et al.: From medical history and biochemical tests to presymptomatic treatment in a large MEN IIa family. J Intern Med 1995, 238:347-356.
45. O'Riordain D, O'Brien T, Weaver A, Hay I: Medullary thyroid carcinoma in multiple endocrine neoplasia Type IIa and lib. Surgery 1994, 116:1017-1023.
46. Eng C, Mulligan LM, Smith DP: Low frequency of germline mutation with RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995, 43:123-127.
47. Noorani H, Khan HN, Gallie BL: Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. Am J Hum Genet 1996, 59:301-307.
48. Graham SM, Genel M, Touloukian JR, et al.: Provocative testing for occult medullary carcinoma of the thyroid: findings in seven children with MEN IIa. J Pediatr Surg 1987, 22:501-503.
49. National Advisory Council for Human Genome Research. Statement on the use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994, 27:785.
50. Bussolati G, Poffi M, Pagani A: Diagnostic problems in medullary carcinoma of the thyroid. Pathol Res Pract 1995, 191:332-344.
51. Perry A, Molberg K, Albores-Saavedra J: Physiologic versus neoplastic C-cell hyperplasia of the thyroid. Cancer 1996, 77:750-756.
52. Saad MF, Ordonez NG, Giodo JJ, Samman NA: The prognostic value of calcitonin immunostaining in MTC. J Clin Endocrinol Metabol 1984, 59:850-856.
53. Pyke MN, Hay ID, Geollner JR, Pyke CM, Bergstrahl EJ: Prognostic significance of calcitonin Immunoreactivity, amyloid staining and flow cytometric DNA measurements in MTC. Surgery 1991, 110:964-971.
54. Kakudo K, Carney JR, Sizemore GW: Medullary carcinoma of the thyroid: biologic behavior of the sporadic and familial neoplasm. Cancer 1985, 55:2818-2821.
55. Cance WG, Wells SA: MEN Type IIa. Curr Probl Surg 1985, 22:7-56.
56. Bergholm U, Adami HO, Bergstrom R: Clinical characteristics in sporadic and familial medullary thyroid carcinoma. Cancer 1989, 63:1196-1204.
57. Samaan N, Hickey R: Medullary carcinoma of the thyroid: differentiating the types and current management Oncology 1987, 1:21-28.
58. Wells SA, Baylin SB, Leight GS, Dale JK, Dilley WG: The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann Surg 1982, 195:595-599.
59. Zeppa P, Vetroni M, Marino F: Fine needle aspiration of medullary thyroid carcinoma. Cytopathology 1990, 1:35-44.
60. Ponder BAJ, Ponder MA, Coffey R, Pembrey ME, Gagel RF: Risk estimate and screening in families of patients with MTC. Lancet 1988, i:397-401.
61. Wells SA, Baylin SB, Gann DS, Farrell RE, Dilley WG, Preissig SH, Linehan M: Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg 1978, 188:377-383.
62. vanHeerden JA, Grant CS, Gharib H, Hay I, Ilstrup DM: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for MTC. Ann Surg 1990, 212:395-400.
63. Gharib H, McConahey WM, Tiegs RD, Bergstrahl EJ, Goellner JR, Sizemak GW: MTC: Clinical pathologic features and long-term follow-up of 65 patients treated from 1946 to 1970. Mayo Clin Proc 1992, 67:934-940.
64. Samaan NA, Schultz PN, Hickey RL: Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiation therapy. J Clin Endocrinol 1988, 67:801-805.
65. Nguyen JD, Chassard JL, Lagarde P: Results of post-operative radiation treatment in MTC: a retrospective study by the French Federation of Cancer Institutes. The Radiotherapy Cooperative Peer Group. Radiother Oncol 1992, 23:1-5.
66. Hay I, Ryan J, Grant C: Prognostic sign of non-diploid DNA determined by flow cytometry in sporadic MTC and FMTC. Surgery 1990, 108:972-980.
67. Dralle H, Scheumann G, Proye C: The value of lymph node dissection in hereditary MTC: a retrospective European multicenter study. J Intern Med 1995, 238:357-361.
68. Ellenhorn J, Shah J, Brennan M: Impact of therapeutic regional lymph node dissection for MTC. Surgery 1993, 114:1078-1082.
69. O'Riordain DS, O'Brien T, Grant GS: Surgical management of primary hyperparathyroidism in MEN Type I and II. Surgery 1993, 114:1031-1039.
70. Wu LT, Averbuch SD, Ball DW: Treatment of advanced MTC with combination cyclophosphamide, vincristine, and decarbonize. Cancer 1994, 73:432.
71. Troncone L, Rufini V, Montenaggi P: The diagnostic and therapeutic utility of radioiodinated MIBG: 5 years' experience. Eur J Nucl Med 1990, 16:325.
72. Modigliani E, Cohen R, Joannidis S, Modigliani E, Cohen R, Joanndis S: Results of long-term continuous subcutaneous octreotide administration In 14 patients with MTC. Clin Endocrinol 1992, 36:183.
73. 131 MIBG therapy in MTC. J Nucl Biol Med 1991, 35:334-336.
74. 131 labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res (Suppl) 1995, 55:5946-5951.
75. Brunt LM, Wells SA: Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 1987, 67:263-279.
76. Rougier P, Parmentier A, Planche A, Lefevre M, Travogli JP: MTC: prognostic factors in treatment. Int J Radiat Oncol Biol Phys 1983, 9(2):161-169.
77. Tisell LE, Dilley WG, Wells SA: Progression of post-operative residual MTC as monitored by plasma calcitonin levels. Surgery 1996, 119:34-39.
78. Chaudhuri R, Clark SE, Bingham JB: Value of MRI in recurrent medullary cell carcinoma of the thyroid: comparison of pentavalent 99 MTC dimercaptosuccinic acid scintlgraphy [abstract]. Radiol Oncol 1991, 74:74.
79. Tung W, Vesely T, Moley J: Laparoscopic detection of hepatic metastasis in patients with residual recurrent medullary thyroid carcinoma. Surgery 1995, 118:1024-1030.
80. Gautvik KM, Talle K, Hager B: Early liver metastasis in patients with medullary carcinoma of the thyroid gland. Cancer 1989, 63:175-180.
81. Dunn JM, Farndon JR: Medullary thyroid carcinoma. Br J Surg 1993, 80:6-9.
82. BenMrad MD, Gardet P, Roche A, Rougier P, Calmette C, Hansson G: Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent MTC. Cancer 1989, 63:133-138.
83. Tisell HE, Hansson G, Jansson S: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. J Surg 1986, 99:60-69.
84. Buhr H, Kallinowski R, Rave F, Herfaith C: Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Cancer 1993, 72:3685-3693.
85. Moley JF, Wells SA, Dilley WG: Reoperation for recurrent or persistent MTC. Surgery 1993, 114:1090-1096.